Trials / Completed
CompletedNCT03165045
Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)
AERIAL®: Changes in Health and Functional Status in Patients With COPD During Therapy With Spiolto® Respimat®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,351 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto® Respimat® according to label after approximately 6 weeks in routine clinical practice.
Detailed description
The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto® Respimat® according to label after approximately 6 weeks in routine clinical practice. In visit 1, patient data on demographics, smoking status, medical history, breathlessness, general condition, health and functional status and adverse drug reactions will be collected. In visit 2, after approximately 6 weeks, data on smoking status, concomitant diseases and medication, general condition, health and functional status and adverse drug reactions will be collected; additionally data on patient satisfaction, continuation or discontinuation of treatment and the reason in case of discontinuation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spiolto® Respimat® | 6 weeks |
Timeline
- Start date
- 2017-05-26
- Primary completion
- 2019-02-04
- Completion
- 2019-03-24
- First posted
- 2017-05-24
- Last updated
- 2020-04-09
- Results posted
- 2020-04-01
Locations
108 sites across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03165045. Inclusion in this directory is not an endorsement.